May 2 – 4, 2013
Location: InterContinental Hotel and Bank of America Conference Center, Cleveland, OH
To view the entire brochure and agenda, please click here.
The premier meeting on biologic therapeutics for autoimmune and autoinflammatory disease,
combining cutting-edge science and real life clinical decision making.
Biologic Therapies V Summit is an advanced course that brings together world leaders in immune-based
therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.
During the three-day meeting, expert faculty will engage in an interactive learning experience with a
sophisticated audience of rheumatologists, gastroenterologists, dermatologists, and other interested health care providers.
The Summit kicks off with a fundamental immunologic plenary session, reviewing recent basic laboratory breakthroughs
in terms of their potential clinical implications.
Also offered will be sessions that provide in-depth analyses of approved agents, new agents, predicting toxicity, clinical
controversies, and new indications.
Join the Cleveland Clinic R.J. Fasenmyer Center for Clinical Immunology and the Cleveland Society of
Rheumatology for these outstanding presentations on the clinical use of biologics to treat autoimmune and
“The Biologics Summit is a great meeting to get a small number of rheumatologists together, with
groundbreaking lectures and the conversations in the hallway. I think these are very important because
that’s how I get a lot of information and get together with my colleagues.”
– Bernard R. Rubin, DO, MPH – Henry Ford Health System, Detroit, MI
As a result of attending this Summit, the participant will be able to do the following:
• Compare and contrast similarities in the pathogenesis and treatments for immune-mediated
inflammatory diseases (IMID) including RA, SLE, spondyloarthropathy, vasculitis, gout, autoinflammatory
diseases, psoriasis, inflammatory bowel disease, and others.
• Discuss the epidemiology and potential immunologic basis of environmental risk factors in the
immunopathogenesis of rheumatoid arthritis.
• Summarize recent research advances in basic immunology, including those involving T cell and B cell
biology, as they apply to the immunopathogenesis and development of novel therapeutics for IMID.
• List the essential steps of intracellular signaling pathways shared among inflammatory cytokines
including JAK-stat, SYK, and others and describe the mechanism of action, immunomodulatory
properties, clinical effectiveness, and potential toxicities for small molecular inhibitors of such pathways.
• Describe the mechanisms of action, indications, and toxicity of newly approved biologic agents,
including monoclonal antibodies, antibody constructs, and small molecules as well as novel agents
in late development, and assess their clinical implications for rheumatology, gastroenterology,
dermatology, and neurology.
• Recognize and manage the challenge of comorbidities associated with use of biologic therapeutics
including serious infections, opportunistic infections, viral hepatitis (HBV and HCV), and
• Assess efficacy and toxicity profiles of existing biologics and new and investigational therapeutic
agents, in and out of class, and describe their potential to meet unmet health care needs.
• Critically appraise the patient care impact of the immunogenicity of biologic therapies, and describe the
potential risks and benefits of biosimilars.
• Enhance decision-making skills for appropriate use of biologic therapies in highly complex clinical situations.
The Summit is directed towards rheumatologists and rheumatology advanced health practitioners,
dermatologists, allergists, gastroenterologists, infectious disease physicians, internal medicine physicians,
neurologists, oncologists, pediatricians, pulmonologists, and associated allied health practitioners interested
in or using biologic therapeutics for autoimmune and inflammatory disorders.